Skip to main content
Top
Published in: Neurological Sciences 4/2024

21-11-2023 | Levodopa | Review Article

A video-atlas of levodopa-induced dyskinesia in Parkinson’s disease: terminology matters

Authors: Harsh V. Gupta, Abhishek Lenka, Rajinder K. Dhamija, Alfonso Fasano

Published in: Neurological Sciences | Issue 4/2024

Login to get access

Abstract

Dyskinesia is a common complication of long-term levodopa therapy in patients with Parkinson’s disease (PD), which often worsens the quality of life. It is usually dose-dependent and emerges possibly due to pulsatile stimulation of dopamine receptors. Delineating the pattern of dyskinesia is crucial for determining the most effective therapeutic approach, a task that often presents challenges for numerous neurologists. This article comprehensively describes various patterns of dyskinesia in PD patients and features video demonstration of some of the common forms of dyskinesia. We have used a real case scenario as an example to lead the discussion on the phenomenology, distinguishing features, and management of various types of dyskinesia. A comprehensive literature search was conducted in PubMed using “dyskinesia” as a keyword. The prototype case with videos highlights the differentiating features of dyskinesia along with the treatment strategies. A wide range of descriptive rubrics have been used for certain dyskinesia which are described in detail in this article. The newer types of dyskinesia associated with continuous dopaminergic stimulation in patients with advanced PD and their implications have been described. As there are distinct ways of managing various types of dyskinesia, understanding the phenomenology and chronology of dyskinesia is vital for the optimal management of dyskinetic PD patients. We suggest that dyskinesia should be classified broadly into peak-dose dyskinesia (PDD), biphasic dyskinesia (BD), and OFF-period dystonia. The occurrence of low-dose dyskinesia and complex dyskinesia of continuous dopaminergic treatments should be known to specialists and will require additional studies.
Appendix
Available only for authorised users
Literature
4.
go back to reference Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D-”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52:163–174PubMed Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D-”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52:163–174PubMed
9.
go back to reference Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47:S2-9 discussion S9-11PubMed Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47:S2-9 discussion S9-11PubMed
10.
go back to reference Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:11–19PubMed Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:11–19PubMed
16.
go back to reference Durif F, Vidailhet M, Debilly B, Agid Y (1999) Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 14:242–245CrossRefPubMed Durif F, Vidailhet M, Debilly B, Agid Y (1999) Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 14:242–245CrossRefPubMed
20.
go back to reference Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA (2009) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson’s disease: A double blind video-based analysis. Mov Disord 24:336–343. https://doi.org/10.1002/mds.22208CrossRefPubMed Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA (2009) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson’s disease: A double blind video-based analysis. Mov Disord 24:336–343. https://​doi.​org/​10.​1002/​mds.​22208CrossRefPubMed
26.
go back to reference Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301CrossRefPubMed Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301CrossRefPubMed
28.
go back to reference Rocha MS, Andrade LA, Ferraz HB, Borges V (1995) Levodopa-induced dyskinesia in 176 patients with Parkinson’s disease. Arq Neuropsiquiatr 53:737–742CrossRefPubMed Rocha MS, Andrade LA, Ferraz HB, Borges V (1995) Levodopa-induced dyskinesia in 176 patients with Parkinson’s disease. Arq Neuropsiquiatr 53:737–742CrossRefPubMed
37.
48.
go back to reference Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O’Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099–1109. https://doi.org/10.1016/S1474-4422(22)00400-8CrossRefPubMed Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O’Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099–1109. https://​doi.​org/​10.​1016/​S1474-4422(22)00400-8CrossRefPubMed
49.
51.
go back to reference Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759. https://doi.org/10.1016/S1474-4422(18)30239-4CrossRefPubMed Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759. https://​doi.​org/​10.​1016/​S1474-4422(18)30239-4CrossRefPubMed
Metadata
Title
A video-atlas of levodopa-induced dyskinesia in Parkinson’s disease: terminology matters
Authors
Harsh V. Gupta
Abhishek Lenka
Rajinder K. Dhamija
Alfonso Fasano
Publication date
21-11-2023
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 4/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-023-07209-6

Other articles of this Issue 4/2024

Neurological Sciences 4/2024 Go to the issue